2024ACC热点速递:REDUCE-AMI和EMPACT-MI临床研究解读  

Highlights from 2024 ACC:Clinical study interpretation of REDUCE-AMI and EMPACT-MI

作　　者：龙琦[1,2,3] 廖梦阳 廖玉华 袁璟[1,2,3] LONG Qi;LIAO Mengyang;LIAO Yuhua;YUAN Jing(Department of Cardiology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,430022,China;Hubei Key Laboratory of Biological Targeted Therapy;Hubei Provincial Engineering Research Center of Immunological Diagnosis and Therapy for Cardiovascular Diseases)

机构地区：[1]华中科技大学同济医学院附属协和医院心内科,武汉430022 [2]生物靶向治疗研究湖北省重点实验室 [3]心血管疾病免疫诊疗湖北省工程研究中心

出　　处：《临床心血管病杂志》2024年第6期444-447,共4页Journal of Clinical Cardiology

基　　金：国家自然科学基金(No:81770378、81800333)。

摘　　要：在2024年4月美国心脏病学会年会上,REDUCE-AMI和EMPACT-MI研究结果公布,分别显示β受体阻滞剂和钠-葡萄糖协同转运蛋白2抑制剂对心肌梗死患者的远期预后无显著获益,引起广泛关注,本文就此进行深入解读。In the 2024 American College of Cardiology(ACC)scientific sessions,the results of the REDUCE-AMI and EMPACT-MI studies showed thatβ-blocker and SGLT2i have not demonstrated significant benefits in the long-term prognosis of patients with myocardial infarction.Because of the widespread attention,we aim to provide an in-depth interpretation of these findings.

关 键 词：急性心肌梗死 心力衰竭 Β受体阻滞剂 钠-葡萄糖协同转运蛋白2抑制剂 

分 类 号：R542.2[医药卫生—心血管疾病]